XBRU:CYAD (Belgium)  
Celyad Oncology logo

Celyad Oncology

€ 1.49 (-0.8%) Sep 29
P/E:
At Loss
P/B:
1.10
Market Cap:
€ 33.66M ($ 32.87M)
Enterprise V:
€ 21.44M ($ 20.94M)
Volume:
16.37K
Avg Vol (2M):
31.99K
Also Trade In:
Volume:
16.37K
Market Cap €:
33.66M
Market Cap $:
32.87M
PE Ratio:
At Loss
Avg Vol (2-Month):
31.99K
Enterprise Value €:
21.44M
Enterprise Value $:
20.94M
PB Ratio:
1.10
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
Name Current Vs Industry Vs History
Cash-To-Debt 6.65
Equity-to-Asset 0.49
Debt-to-Equity 0.07
Debt-to-EBITDA -0.09
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -3.43
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 9.66
9-Day RSI 15.59
14-Day RSI 23.49
6-1 Month Momentum % -2.38
12-1 Month Momentum % -42.33

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.71
Quick Ratio 1.71
Cash Ratio 1.27

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -23.7

Profitability Rank

Name Current Vs Industry Vs History
ROE % -83.12
ROA % -38.59
ROIC % -58.44
ROC (Joel Greenblatt) % -789.76
ROCE % -46.67

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.1
EV-to-EBIT -0.84
EV-to-EBITDA -0.84
EV-to-FCF -0.79
Earnings Yield (Greenblatt) % -119.05

Financials (Next Earnings Date:2022-11-10)

XBRU:CYAD's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0
EPS (TTM) (€) -1.3
Beta 1.39
Volatility % 36.15
14-Day RSI 23.49
14-Day ATR (€) 0.103629
20-Day SMA (€) 1.841
12-1 Month Momentum % -42.33
52-Week Range (€) 1.41 - 4.6
Shares Outstanding (Mil) 22.59

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Celyad Oncology Filings

Document Form Filing Date
No Filing Data

Celyad Oncology Analysis

Share your research